Cai Jing Wang
Search documents
施华洛世奇将裁员约400人
Cai Jing Wang· 2025-11-11 05:36
这项计划预计将在2026年底前完成,届时总部员工数量将从目前的约2480人减少至2100人,据公司声 明,裁员将通过多种方式进行,包括解雇、自愿离职和退休。 据Swarovski施华洛世奇消息,将对其位于奥地利瓦滕斯的总部进行大规模裁员与重组,计划裁减约400 个岗位。 (Swarovski施华洛世奇) ...
保利发展11.07亿元摘得青羊地块
Cai Jing Wang· 2025-11-11 05:33
Core Insights - Poly Developments acquired a land parcel in Chengdu for a base price of 1.107 billion yuan, with a floor price of 16,500 yuan per square meter [1] Group 1: Land Acquisition Details - The land parcel is located in the Su Po Street area of the Qingyang District, covering a total area of 33,545.32 square meters (approximately 50.318 acres) [1] - The planned construction area for the site is 67,090.64 square meters, with a plot ratio of 2.0 [1] - The site is bordered by Bai Ren Road to the west, Bai Rui Road to the south, and is adjacent to the Poplar Tree Middle School (Bai Ren Branch) to the east, with vacant land to the north [1] Group 2: Surrounding Area and Development Potential - The land is situated in the Wai Jin Sha area, which is characterized by mature development and adequate amenities to meet daily living needs [1]
上海医药:两款药品通过仿制药一致性评价
Cai Jing Wang· 2025-11-11 05:24
呼吸道感染、耳鼻喉感染、泌尿系感染、皮肤和软组织感染、败血症、脑膜炎、淋病、骨和关节感染及 产褥期和妇科感染,最早由GSK公司研发,于1978在英国、意大利等国家上市。IQVIA数据库显示, 2024年中国大陆医院采购头孢呋辛钠注射剂金额为人民币26.2亿元。 注射用氨曲南适用于治疗敏感革兰氏阴性菌引起的感染:尿路(复杂和单纯 的)、下呼吸道感染、败 血症、皮肤和皮肤结构感染、腹腔内感染和妇科感染, 由BMS公司研发,最早于1984年在意大利上 市。IQVIA 数据库显示,2024年中国大陆医院采购氨曲南注射剂金额为人民币1.63亿元。 近日,上海医药发布公告称,公司下属上海上药新亚药业有限公司的注射用头孢呋辛钠、注射用氨曲南 收到国家药品监督管理局颁发的《药品补充申请批准通知书》,前述药品通过仿制药质量和疗效一致性 评价。 (编辑:杨燕 林辰)关键字: 医疗 公告显示,注射用头孢呋辛钠适用于治疗以下疾病中特定微生物敏感菌株引起的感染: (上海医药公告) ...
上纬新材将发布1.88米全尺寸机器人,智元称其独立开展业务
Cai Jing Wang· 2025-11-11 05:10
#上纬新材发布机器人预告# 【#智元回应上纬新材将发布机器人# 】11月11日上午,根据"智元上纬"公 众号发布消息,上纬新材将发布一款身高1.88米的全尺寸机器人。智元机器人随后回应,上纬新材是独 立开展具身智能业务,并非联合智元开展。(第一财经) ...
首旅酒店:携程上海减持2520.6万股公司股份
Cai Jing Wang· 2025-11-11 02:58
Core Viewpoint - The announcement indicates that Ctrip Travel Information Technology (Shanghai) Co., Ltd. has reduced its stake in Shoulu Hotel by 25,206,000 shares, representing 2.26% of the total share capital, bringing its ownership down to 10% from 12.26% [1] Group 1 - Ctrip Shanghai executed a block trade to reduce its shareholding in Shoulu Hotel [1] - The reduction in shareholding touches the 1% threshold and the 5% whole number multiple [1] - The transaction occurred on November 10, 2025 [1]
启迪药业:公司提交的“古汉养生健康产业集团股份公司”名称变更方案未获批
Cai Jing Wang· 2025-11-11 02:58
Core Viewpoint - Qidi Pharmaceutical announced the cancellation of a proposal to change its name to "Guhan Health Industry Group Co., Ltd." due to the lack of approval from market supervision authorities [1] Group 1 - The company's board of directors held a temporary meeting on September 16, where the decision to cancel the name change proposal was made [1] - The company emphasized that any future name change plans will comply with legal and regulatory requirements for timely information disclosure [1] - "Guhan," as an established brand under the company, has built a strong reputation and goodwill in the market [1] Group 2 - The company plans to leverage the "Guhan" brand as a key resource to enhance research and development as well as market promotion efforts [1] - The focus on the "Guhan" brand aims to further improve performance and brand influence [1]
联通智网科技启动上市辅导



Cai Jing Wang· 2025-11-11 02:57
Group 1 - The core point of the article is that Unicom Smart Network Technology Co., Ltd. has initiated the listing guidance process, with China International Capital Corporation serving as the advisory institution [1] - China United Network Communications Co., Ltd. directly holds 68.88% of the shares in Unicom Smart Network Technology Co., Ltd. [1] - Additionally, China United Network Communications Co., Ltd. holds an indirect stake of 0.33% through its wholly-owned subsidiary, Unicom Venture Capital [1]
中建八局承建的上海临港拓荆科技项目正式竣工投产
Cai Jing Wang· 2025-11-11 02:53
项目投入使用后,将成为上海临港新片区半导体产业链的关键一环,为区域半导体产业的集聚发展提供 坚实的硬件支撑,助力打造完整、高效的半导体产业生态。 (中建八局) 据悉,上海拓荆科技项目坐落于上海市临港新片区,总建筑面积9.07万平方米,涵盖1、2#生产车间、 食堂宿舍楼,研发楼及相关配套附属建筑。 11月11日消息,近日,由中建八局承建的上海临港拓荆科技项目正式竣工投产。 ...
松霖科技:2025年首启机器人业务,护理服务机器人系统主要向康养机构、医美机构
Cai Jing Wang· 2025-11-11 02:45
Core Viewpoint - Songlin Technology positions its robotics business as a strategic segment, set to launch in 2025, with a dual business model targeting both domestic and international markets [1] Group 1: Business Model - The first business model focuses on B-end customers, offering proprietary brand robots that provide a comprehensive solution combining hardware and self-developed algorithms based on scene requirements [1] - Applications for the B-end model include logistics and nursing service robots, with specific systems for security inspection, internal logistics distribution, and concierge services [1] - The second model operates under the IDM framework for consumer-grade robots, selling products like AI toy robots, AI companion robots, and consumer-grade exoskeleton robots through leading overseas brand clients [1] Group 2: Financial Performance - For the period from January to September 2025, Songlin Technology reported revenue of 1.852 billion yuan, a year-on-year decrease of 15.49% [1] - The company achieved a net profit attributable to shareholders of 159 million yuan, reflecting a year-on-year decline of 50.53% [1]
Ralph Lauren2026财年第二季度营收同比增长16.5%至20.1亿美元
Cai Jing Wang· 2025-11-11 02:36
Core Insights - Ralph Lauren reported a 16.5% year-over-year revenue increase to $2.01 billion for Q2 of fiscal year 2026, with net profit rising 40% to $208 million [1] - All regions experienced double-digit growth, with Asia and Europe showing the most significant increases of 17% and 22% to $446 million and $688.3 million, respectively; North America saw a revenue growth of 12.6% to $832 million [1] - The company added 1.5 million consumers through its Direct-to-Consumer (DTC) channel, with average retail sales in DTC growing by 12% [1] - Core business achieved double-digit growth, driven by strong sales of wool knitwear, cashmere sweaters, cotton sweaters, linen shirts, and seasonal Oxford shirts [1] - Due to the strong performance, the company raised its fiscal year 2026 revenue forecast, now expecting an annual growth of 5% to 7% [1]